1. **NAME OF THE MEDICINAL PRODUCT**

Serdolect

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each 4 mg tablet contains: sertindole 4 mg
Each 12 mg tablet contains: sertindole 12 mg
Each 16 mg tablet contains: sertindole 16 mg
Each 20 mg tablet contains: sertindole 20 mg

3. **PHARMACEUTICAL FORM**

Film-coated tablets.
Description of the tablets:
4 mg: Oval, yellow, biconvex tablet marked with “S4” on one side.
12 mg: Oval, beige, biconvex tablet marked with “S12” on one side.
16 mg: Oval, rose, biconvex tablet marked with “S16” on one side.
20 mg: Oval, pink, biconvex tablet marked with “S20” on one side.
For excipients see section 6.1.

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**
Sertindole is indicated for the treatment of schizophrenia.

Due to cardiovascular safety concerns, sertindole should only be used for patients intolerant to at least one other antipsychotic agent.

Sertindole should not be used in emergency situations for urgent relief of symptoms in acutely disturbed patients.

4.2 **Posology and method of administration**
Sertindole is administered orally as one daily dosage with or without meals. In patients where sedation is required, a benzodiazepine may be co-administered.

**Note:** ECG monitoring is required before and during treatment with sertindole (see section 4.4).
Clinical studies have shown that sertindole prolongs the QT interval to a greater extent than some other antipsychotics. Sertindole should therefore only be used for patients intolerant to at least one other antipsychotic agent. Prescribing physicians should comply fully with the required safety measures (see sections 4.3 and 4.4).
**Titration**
Initially 4 mg sertindole daily is administered to all patients. The dose should be increased by increments of 4 mg after 4-5 days on each dose until the optimal daily maintenance dose, within the range of 12-20 mg, is reached. Due to the $\alpha_1$-blocking activity of sertindole, symptoms of postural hypotension may occur during the initial dose-titration period. A starting dose of 8 mg or a rapid increase in dose carries a significantly increased risk of postural hypotension.

**Maintenance**
Dependent on individual patient response, the dose may be increased to 20mg/day. Only in exceptional cases should the maximum dose of 24mg be considered, as clinical trials have not demonstrated consistently improved efficacy above 20mg and the risk of QT prolongation may be increased at the upper end of the dose range.

The blood pressure of the patients should be monitored during titration and early maintenance treatment.

**Elderly**
A pharmacokinetic study showed no difference between young and elderly subjects. However, only limited clinical trial data exist for patients greater than 65 years of age. Treatment should only be initiated after a thorough cardiovascular examination. Slower titration and lower maintenance doses are recommended in elderly patients (see section 4.4).

**Children and adolescents under the age of 18**
The safety and efficacy of sertindole in children and adolescents have not been established.

**Reduced renal function**
Sertindole can be given at the usual dosage to patients with renal impairment (see section 4.3). The pharmacokinetics of sertindole is not affected by haemodialysis.

**Reduced hepatic function**
Patients with mild/moderate hepatic impairment require slower titration and a lower maintenance dose.

**Re-introduction of discontinued treatment**
When restarting sertindole treatment in patients who have had an interval of less than one week without sertindole, re-titration of sertindole is not required and their maintenance dose can be re-introduced. Otherwise the recommended titration schedule should be followed. An ECG should be taken prior to re-titration of sertindole.

**Switching from other antipsychotics**
Treatment with sertindole can be initiated according to the recommended titration schedule concomitantly with cessation of other oral antipsychotics. For patients treated with depot antipsychotics, sertindole is initiated in place of the next depot injection.

4.3 Contraindications
Hypersensitivity to sertindole or any of the excipients.

Sertindole is contraindicated in patients with known uncorrected hypokalaemia, and those with known uncorrected hypomagnesaemia.

Sertindole is contraindicated in patients with a history of clinically significant cardiovascular disease, congestive heart failure, cardiac hypertrophy, arrhythmia, or bradycardia (<50 beats per minute). Furthermore, sertindole should not be initiated in patients with congenital long QT syndrome or a family history of this disease, or in patients with known acquired QT interval prolongation (QTc above 450 msec in males and 470 msec in females).

Sertindole is contraindicated in patients receiving drugs known to significantly prolong the QT interval. Relevant classes include:
- class Ia and III antiarrhythmics (e.g. quinidine, amiodarone, sotalol, dofetilide)
- some antipsychotics (e.g. thioridazine)
- some macrolides (e.g. erythromycin)
- some antihistamines (e.g. terfenadine, astemizole)
- some quinolone antibiotics (e.g. gatifloxacin, moxifloxacin).

The above list is not exhaustive. Other individual drugs known to significantly increase QT interval (e.g. cisapride, lithium) are also contraindicated.

Sertindole is contraindicated in patients with severe hepatic impairment.

4.4 Special warnings and special precautions for use

Cardiovascular
Clinical studies have shown that sertindole prolongs the QT interval to a greater extent than some other antipsychotics. The mean QT prolongation is greater at the upper end of the recommended dose range (20 and 24 mg). Prolongation of the QTc interval in some drugs is associated with the ability to cause Torsade de Pointes-type (TdP) arrhythmia (a potentially fatal polymorphic ventricular tachycardia) and sudden death. However, clinical and non-clinical data have been unable to confirm whether sertindole is more arrhythmogenic than other antipsychotics. Sertindole should therefore only be used for patients intolerant to at least one other antipsychotic agent.
Prescribing physicians should comply fully with the required safety measures.

**ECG monitoring:**
- ECG monitoring is mandatory prior to and during treatment with sertindole.
- Sertindole is contraindicated if a QTc interval of more than 450 msec in males or 470 msec in females is observed at baseline.
- ECG monitoring should be conducted at baseline, upon reaching steady state after approximately 3 weeks or when reaching 16 mg and again after 3 months of treatment.
  During maintenance therapy an ECG is required every 3 months.
- During maintenance treatment, ECG measurements should take place prior to and after any increase in dose.
- An ECG is recommended after the addition or increase of dosage of concomitant medication that may increase the sertindole concentration (see section 4.5).
- If a QTc interval of more than 500 msec is observed during treatment with sertindole, treatment with sertindole should be discontinued.
- For patients with symptoms such as palpitations, convulsions, or syncope that could indicate the occurrence of arrhythmias, the prescriber should initiate urgent evaluation, including an ECG.
- ECG monitoring is ideally conducted in the morning and the Bazett or Fridericia formulae for calculating the QTc interval are preferred.

The risk of QT prolongation is increased in patients receiving concomitant treatment with drugs that prolong the QTc interval or drugs that inhibit sertindole metabolism (see section 4.3).

Baseline serum potassium and magnesium levels should be measured before commencing treatment with sertindole in patients at risk of significant electrolyte disturbances. Low serum potassium and magnesium should be corrected before proceeding with treatment. Monitoring of serum potassium is recommended for patients experiencing vomiting, diarrhoea, treatment with potassium-depleting diuretics, or other electrolyte disturbances.

Due to the α1-blocking activity of sertindole, symptoms of postural hypotension may occur during the initial dose-titration period.

Antipsychotic drugs may inhibit the effects of dopamine agonists. Sertindole should be used cautiously in patients with Parkinson’s disease.

Some SSRIs, like fluoxetine and paroxetine (potent CYP2D6 inhibitors), may increase the plasma levels of sertindole by a factor of 2 - 3. Sertindole should therefore only be used concomitantly with these drugs with extreme caution, and only if the potential benefit outweighs the risk. A lower maintenance dose of sertindole may be needed and careful ECG monitoring should be undertaken before and after any dose adjustment of these drugs (see section 4.5).
Sertindole should be used with caution in patients who are known to be poor CYP2D6 metabolisers (see section 4.5).

Use in the elderly
In view of the increased risk of significant cardiovascular disease in the elderly, sertindole should be used with care in patients above 65 years of age. Treatment should only be initiated after a thorough cardiovascular examination (see section 4.2)

**Reduced hepatic function**
Patients with mild/moderate hepatic dysfunction should be closely observed. Slower titration and a lower maintenance dose are recommended.

**Tardive dyskinesia**
Tardive dyskinesia is thought to be caused by dopamine receptor hypersensitivity in the basal ganglia as a result of chronic receptor blockade by antipsychotics. A low incidence (comparable to that of placebo) of extrapyramidal symptoms during treatment with sertindole has been seen in clinical studies. However, long-term treatment with antipsychotic compounds (especially at high dosages) is associated with the risk of tardive dyskinesia. If signs of tardive dyskinesia appear, dosage reduction or drug discontinuation should be considered.

**Seizures**
Sertindole should be used with caution in patients with a history of seizures.

**Neuroleptic Malignant Syndrome**
A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs. The management of NMS should include immediate discontinuation of antipsychotic drugs.

**Withdrawal**
Acute withdrawal symptoms, including nausea, vomiting, sweating, and insomnia have been described after abrupt cessation of antipsychotic drugs. Recurrence of psychotic symptoms may also occur, and the emergence of movement disorders (such as akathisia, dystonia and dyskinesia) has been reported. Therefore, a gradual reduction of dosage is recommended.

**Excipients** The tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not receive this medicine.

**4.5 Interactions with other medicinal products and other forms of interaction**
Prolongation of the QT interval during sertindole treatment may be exacerbated by the co-administration of other drugs known to significantly increase the QT interval. Co-administration of such drugs is therefore contraindicated (see section 4.3). Such an interaction may occur e.g. between quinidine and sertindole. In addition to the effects on QT interval prolongation (see section 4.3), CYP2D6 is markedly inhibited by quinidine.
Sertindole is extensively metabolised by the CYP2D6 and CYP3A isozymes of the cytochrome P450 system. CYP2D6 is polymorphic in the population and both isozymes can be inhibited by a variety of psychotropic and other drugs (see section 4.4).

**CYP2D6**
The plasma concentration of sertindole is increased by a factor of 2 - 3 in patients concurrently taking fluoxetine or paroxetine (both potent CYP2D6 inhibitors). Sertindole should therefore only be used concomitantly with these or other CYP2D6 inhibitors with extreme caution. A lower maintenance dose of sertindole may be needed and careful ECG monitoring should be undertaken before and after any dose adjustment of these drugs (see section 4.4).

**CYP3A**
Minor increases (<25%) in sertindole plasma concentrations have been noted for macrolide antibiotics (e.g. erythromycin, a CYP3A inhibitor) and calcium channel antagonists (diltiazem, verapamil). However, the consequences could be greater in CYP2D6 poor metabolisers since elimination of sertindole by both CYP2D6 and CYP3A would be affected. Because it is not possible to routinely identify patients who are poor metabolisers of CYP2D6, the concomitant administration of CYP3A inhibitors and sertindole is contraindicated, as this may lead to significant increases in sertindole levels (see section 4.3).

The metabolism of sertindole may be significantly enhanced by agents known to induce CYP isozymes, notably rifampicin, carbamazepine, phenytoin and phenobarbital, which can decrease the plasma concentrations of sertindole by a factor of 2 to 3. Reduced antipsychotic efficacy in patients receiving these drugs or other inducing agents may require the dose of sertindole to be adjusted to the upper dosage range.

### 4.6 Pregnancy and lactation

**Pregnancy**
The safety of sertindole for use during pregnancy has not been established.

Sertindole was not teratogenic in animal reproduction studies. A peri/postnatal study in rats showed a decrease in offspring fertility at a dose within the therapeutic range for humans (see section 5.3).

Consequently, sertindole should not be used during pregnancy.

**Lactation**
Studies in nursing mothers have not been performed. Sertindole is expected to be excreted in breast milk.

If treatment with sertindole is considered necessary, discontinuation of breast-feeding should be considered.

### 4.7 Effects on ability to drive and use machines
Sertindole is not sedative, however, patients should be advised not to drive or operate machinery until their individual susceptibility is known.

### 4.8 Side effects
In clinical trials, adverse events with an incidence greater than 1% associated with the use of sertindole and significantly different from placebo were (listed in order of decreasing frequency): rhinitis/nasal congestion, abnormal ejaculation (decreased ejaculatory volume), dizziness, dry mouth, postural hypotension, weight gain, peripheral oedema, dyspnoea, paraesthesia, and prolonged QT interval (see section 4.4).

Extrapyramidal Symptoms (EPS)
The incidences of patients treated with sertindole reporting EPS-related adverse events were similar to those of patients treated with placebo. In placebo-controlled clinical trials, the number of patients requiring anti-EPS medication was the same in the group receiving sertindole as in the group of placebo-treated patients.

Some of the adverse drug reactions will appear at the beginning of treatment and disappear with continuous treatment, e.g., postural hypotension.

The table below shows adverse reactions sorted by system organ class and frequency:

<table>
<thead>
<tr>
<th>Frequency</th>
<th>System Organ Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very common (&gt;10%)</td>
<td>Metabolism and nutritional disorders</td>
</tr>
<tr>
<td>Common (1-10%)</td>
<td>Nervous system disorders</td>
</tr>
<tr>
<td>Uncommon (0.1-1%)</td>
<td>Cardiac disorders</td>
</tr>
<tr>
<td>Rare (0.01-0.1%)</td>
<td>Vascular disorders</td>
</tr>
<tr>
<td>Very rare (&lt;0.01%)</td>
<td>Respiratory, thoracic and mediastinal disorders</td>
</tr>
</tbody>
</table>

**Metabolism and nutritional disorders**
- Uncommon Hyperglycaemia

**Nervous system disorders**
- Common Dizziness, paraesthesia
- Uncommon Syncope, convulsion, movement disorder (in particular tardive dyskinesia, see section 4.4)
- Rare Cases reported as Neuroleptic Malignant Syndrome (NMS) have been received in association with sertindole (see section 4.4)

**Cardiac disorders**
- Common Peripheral oedema
- Uncommon Torsade de Pointes (see section 4.4)

**Vascular disorders**
- Common Postural hypotension (see section 4.4)

**Respiratory, thoracic and mediastinal disorders**
- Very common Rhinitis/nasal congestion
- Common Dyspnoea

**Gastrointestinal disorders**
- Common Dry mouth

**Reproductive system and breast disorders**
- Common Abnormal ejaculation (decreased ejaculatory volume)

**Investigations**
- Common Weight gain, prolonged QT interval, red blood cells urine positive, white blood cells urine positive

4.9 Overdose
Experience with sertindole in acute overdose is limited. Fatal cases have occurred. However, patients taking estimated dosages up to 840 mg have recovered without sequelae. Reported signs and symptoms of overdose were somnolence, slurred speech, tachycardia, hypotension, and transient prolongation of the QT interval. Cases of Torsade de Pointes have been observed, often in combination with other drugs known to induce TdP.

**Treatment**

In case of acute overdose, establishment of an airway and maintenance of adequate oxygenation should be ensured.

Continuous monitoring of ECG and vital signs should commence immediately. If the QTc interval is prolonged, it is recommended that the patient be monitored until the QTc interval has normalised. A half-life of sertindole of 2 to 4 days should be taken into account.

Intravenous access should be established, and the administration of activated charcoal with laxative should be considered. The possibility of multiple drug involvement should be considered.

There is no specific antidote to sertindole and it is not dialysable, therefore appropriate supportive measures should be instituted. Hypotension and circulatory collapse should be treated with appropriate measures such as intravenous fluids. If sympathomimetic agents are used for vascular support, adrenaline and dopamine should be used with caution, since β stimulation combined with α₁ antagonism associated with sertindole may worsen hypotension.

If antiarrhythmic therapy is administered, agents such as quinidine, disopyramide, and procainamide carry a theoretical hazard of QT interval-prolonging effects that might be additive to those of sertindole.

In cases of severe extrapyramidal symptoms, anticholinergic medication should be administered. Close medical supervision and monitoring should continue until the patient recovers.

5. **PHARMACOLOGICAL PROPERTIES**

5.0 **Therapeutic classification**

Pharmacotherapeutic classification: Limbic selective antipsychotics N 05 AE 03.

5.1 **Pharmacodynamic properties**

It is believed that the neuropharmacological profile of sertindole, as an antipsychotic drug, is derived from its selective inhibitory effect on mesolimbic dopaminergic neurons and is due to balanced inhibitory effects on central dopamine D₂ and serotonin 5HT₂ receptors as well as on α₁-adrenergic receptors.

In animal pharmacology studies, sertindole inhibited spontaneously active dopamine neurons in the mesolimbic ventral tegmental area (VTA) in the brain with a selectivity ratio of more than 100 compared to dopamine neurons in substantia nigra pars compacta (SNC). Inhibition of SNC
activity is thought to be involved in movement side effects (EPS) associated with many antipsychotic drugs.

Antipsychotic drugs may cause an increase in serum prolactin levels through dopamine blockade. The prolactin levels in patients receiving sertindole remained within normal limits, both in short-term studies and during long-term treatment (one year).

Sertindole has no effect on muscarinic and histaminic H1 receptors. This is confirmed by the absence of anticholinergic and sedative effects related to those receptors.

5.2 Pharmacokinetic properties
Elimination of sertindole occurs via hepatic metabolism, with a mean terminal half-life of approximately 3 days. The clearance of sertindole decreases with multiple dosing to a mean around 14 l/h (females have approximately 20% lower apparent clearance than males, although lean-mass corrected clearances are comparable). Therefore, upon multiple dosing, accumulation is greater than predicted from a single dose, due to an increase in the systemic bioavailability. However, at steady state, clearance is dose independent and plasma concentrations are proportional to dose. There is moderate inter-subject variability in sertindole pharmacokinetics, due to the polymorphism in the cytochrome P450 2D6 (CYP2D6). Patients who are deficient in this hepatic enzyme have sertindole clearances that are ½ to ⅓ of those who are CYP2D6 extensive metabolisers. These poor metabolisers (up to 10% of the population) will therefore have plasma levels 2 - 3 times the normal. Sertindole concentration is not predictive of therapeutic effect for an individual patient; thus, dosing individualisation is best achieved by assessment of therapeutic effect and tolerability.

Absorption
Sertindole is well absorbed with a $t_{\text{max}}$ of sertindole after oral administration of approximately 10 hours. All tablet strengths are bioequivalent. Food and aluminium-magnesium antacids have no clinically significant effect on the rate or the extent of sertindole absorption.

Distribution
The apparent volume of distribution ($V_d/F$) of sertindole after multiple dosing is approximately 20 l/kg. Sertindole is about 99.5% bound to plasma proteins, primarily to albumin and $\alpha_1$-acid glycoprotein. In patients treated with recommended doses, 90% of the measured concentrations are below 140 ng/ml (~320 nmol/l). Sertindole penetrates into red blood cells with a 1.0 blood/plasma ratio. Sertindole readily penetrates the blood-brain and placental barriers.

Metabolism
Two metabolites have been identified in human plasma: dehydrosertindole (oxidation of the imidazolidinone ring) and norsertindole (N-dealkylation). Plasma concentrations of dehydrosertindole and norsertindole are approximately 80% and 40%, respectively, of the sertindole concentration at steady state. Sertindole activity is primarily due to the parent drug and the metabolites do not appear to have significant pharmacological effects in humans.
Excretion
Sertindole and its metabolites are eliminated very slowly, with a total recovery of 50-60% of a radiolabelled oral dose 14 days after administration. Approximately 4% of the dose is excreted into the urine as parent drug plus metabolites of which less than 1% is present as parent drug. Faecal excretion is the major route of excretion and accounts for the rest of the parent drug and metabolites.

5.3 Preclinical safety data
QT prolongation on the ECG, possibly due to inhibition of the delayed rectifier potassium channel (I_{Kr}, HERG), has been observed in animal studies. However, sertindole shows absence of early after-depolarisations in cardiac rabbit and dog purkinje fibres. Early after-depolarisations are considered essential to trigger Torsade de Pointes. Sertindole did not induce Torsade de Pointes ventricular arrhythmias in atrio-ventricular node ablated rabbit hearts, despite experimental introduction of severe hypokalaemia (1.5 mmol) and bradycardia. The extrapolation of animal findings to humans with regard to QT prolongation and arrhythmia must be undertaken with caution as significant inter-species differences may exist.

The acute toxicity of sertindole is low. In chronic toxicity studies in the rat and dog (3 to 5 times clinical exposure), several effects were observed. These effects are in line with the pharmacological properties of the drug. Animal reproduction studies have not given evidence of teratogenic effects. A periprostnatal study in rats showed a decrease in offspring fertility at a dose within the therapeutic range for humans (0.2 mg/kg/day). At higher dosages, a decreased offspring survival in the early lactation period, reduced weight gain, and delayed development in doses producing maternal toxicity.

Mating and fertility were affected in adult male rats at dosages of 0.14 mg/kg/day and above. The adult fertility impairment, which was reversible, was ascribed to the pharmacological profile of sertindole.

Sertindole was not toxic in a battery of in vitro and in vivo genotoxicity studies. Carcinogenicity studies conducted in the mouse and rat did not indicate any development of tumours relevant to the clinical use of sertindole.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Tablet core
Maize starch, lactose monohydrate, hypromellose, microcrystalline cellulose, croscarmellose sodium, magnesium stearate.

Tablet coating
Hypropromellose, titanium dioxide (E171), macrogol 400, and
4 mg: Iron oxide yellow (E172)
12 mg: Iron oxide yellow (E172), iron oxide red (E172)
16 mg: Iron oxide red (E172)
20 mg: Iron oxide yellow (E172), iron oxide red (E172), iron oxide black (E172).

6.2 Incompatibilities
Not applicable.

6.3 Shelf life
4 mg, 12 mg, 16 mg and 20 mg: 5 years.

6.4 Special precautions for storage
The tablets should be stored in the original package in order to protect from light.

6.5 Nature and contents of container
- PVC/PVdC laminate (clear or white) blister with aluminium foil, inside a carton blackened on the inside, containing 20, 28, 30, 50, 98, or 100 tablets.
- Grey polypropylene container of 100 tablets.

Not all pack sizes may be marketed.

6.6 Instructions for use and handling
None.

6.7 MARKETING AUTHORISATION HOLDER
Lundbeck Israel Ltd
94 Em Hashvot
Petah Tikva

6.8 Manufacture
Lundbeck H A/S
Ottiliavej 9
2500 Valby
Denmark

DATE OF FIRST AUTHORISATION
December 2, 1996

DATE OF REVISION OF THE TEXT
January 18, 2006

09-10-2007